Universal Health Services Inc (UHS)
🔔 Watch stock
Stock Watch
Stock Watch will tell you what changes at Universal Health Services Inc.
Later $1 a month per stock — signing up is free, and you'll be the first to know when it launches.
Appears in These Scanners
This stock currently matches 8 of our scanner strategies — each hit links to the scanner.
Only genuine hits from verified scanners count; pure ranking metrics (P/E, P/S, and similar, which just sort the whole universe) don't count as a hit. View all scanners
Trading Day
Key levels of the most recently completed trading day — not a live quote.
52-Week Range
Current price 169.00 $ — 27% of the range above the low.
Lowest and highest closing price over the last 52 weeks. The marker shows where the current price sits within that range: close to the high speaks for strength, close to the low for weakness.
Basics
Performance
Technical Indicators
Calculated from the price history · as of 08/04/2026
Valuation
Profitability
Balance Sheet & Safety
Growth
Dividend
Quality & Screener
AAQS
8/10The AAQS (AlleAktien Quality Score) checks 10 quality criteria on growth, profitability, and balance-sheet strength — per the methodology developed and published by AlleAktien, calculated by us from our own fundamental data. A stock counts as a quality stock from 9 out of 10 points. Where a company has a shorter listing history, we calculate over the fiscal years available (at least five).
- Sales growth 10Y > 5% 6.6%
- Exp. sales growth 3Y > 5% 6.0%
- EBIT growth 10Y > 5% 5.0%
- Exp. EBIT growth 3Y > 5% 2.3%
- Net debt < 4x EBIT 2.7x
- EBIT positive, 10Y straight 10
- Max. EBIT decline < 50% 26.4%
- Return on equity > 15% 46.4%
- ROCE > 15% 15.7%
- Expected return > 10% 10.8%
View all AAQS quality stocks · Read the methodology at AlleAktien
Source: fundamental data
AI Rating
–Not yet rated — we only show a category once an SEC-backed file with at least two cited passages is available. How the Rating Is Built
Growth Score
6 of 10 Solid growthTen checks against the annual reports — each one passed counts a point.
- Revenue grows by more than 15% a year over three years 9.0% failed
- More than 10% revenue growth is expected for the coming year 4.7% failed
- Share count grows by less than 3% a year -4.4% passed
- Revenue growth plus cash-flow margin add up to at least 40 ("Rule of 40") 14.6% failed
- Gross margin at 40% or higher and without meaningful erosion 90.5% passed
- Goodwill from acquisitions does not grow faster than revenue 25.0% passed
- Net debt below twice EBITDA 2.0 x EBITDA passed
- Operating cash flow covers the profits of the last three years 1,851 m passed
- Return on capital at 15% or higher, or up versus two years ago 15.7% passed
- Insiders hold at least 10% or are net buyers 4.8% failed
A criterion without figures counts neither as passed nor as failed; a score is only produced from 7 judgeable criteria upwards. Source: fundamental data. All ten criteria in detail
Highlighted are things our editorial team noticed: green = stands out as strong, red = deserves a closer look. No single metric is a verdict on its own — always read it in context.
Analysts & Price Target
The price target sits 14.7% above the current price.
- Consensus
- Sell
- Analyst Ratings
- 19
Combined picture of the price targets and recommendations of every analyst covering the stock. Price targets are expectations for the next 12 months, not promises — and they often follow the price rather than predict it.
Estimates by Fiscal Year
| Fiscal Year | EPS Estimate ($) | EPS Range ($) | Revenue Estimate ($M) | Expected Growth | Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 22.58 | 20.68 – 23.59 | 18,609 | 3.9% | 14 |
| 12/31/2027 | 24.19 | 22.05 – 25.96 | 19,502 | 7.1% | 14 |
Average of the analyst estimates for the coming fiscal years. The range shows how far the most optimistic and the most cautious estimate sit apart — the wider it is, the less certain the expectation.
Revenue & Profit
Cash Flow
Balance Sheet
Margins
Per Share
Click the chart or tab into it, then use ← and → to step through the periods.
None of the selected stocks reports this metric. Pick another metric or switch between annual and quarterly.
· Total · per year
These companies report in different currencies — switch on “Indexed” or pick a margin for a fair comparison.
The figures could not be loaded right now.
Source: fundamental data
Quarterly Figures
| Quarter | EPS (Earnings Per Share) | EPS YoY (%) | Sales ($M) | Sales YoY (%) | Net Margin (%) | OCF ($M) | FCF ($M) |
|---|---|---|---|---|---|---|---|
| 2024: Q4 | 4.96 | 57.00 | 4,114 | 11.10 | 8.10 | 658 | 413 |
| 2025: Q1 | 4.80 | 25.40 | 4,100 | 6.70 | 7.70 | 360 | 121 |
| 2025: Q2 | 5.43 | 27.70 | 4,284 | 9.60 | 8.20 | 549 | 283 |
| 2025: Q3 | 5.74 | 51.10 | 4,495 | 13.40 | 8.30 | 381 | 133 |
| 2025: Q4 | 6.92 | 39.60 | 4,486 | 9.10 | 9.90 | 575 | 294 |
| 2026: Q1 | 5.65 | 17.80 | 4,495 | 9.60 | 7.80 | 402 | 185 |
- EPS (Earnings Per Share):
- Quarterly profit divided by the total share count — how much of the profit works out to a single share.
- YoY (Year over Year):
- Change versus the same quarter a year ago — this is how you compare without seasonal distortion (e.g. the holiday shopping season).
- Sales:
- All revenue for the quarter, before any costs are deducted — the top line of the income statement.
- Net Margin:
- What percentage of sales is left over as profit in the end. Negative means the company is posting a loss.
- OCF (Operating Cash Flow):
- The cash that actually flows into the till from the core business during the quarter — harder to dress up than book profit.
- FCF (Free Cash Flow):
- Operating cash flow minus capital expenditures — the money that's genuinely free to use, say for paying down debt, buybacks, or dividends.
Annual Figures
| Fiscal Year | Revenue ($M) | EBIT ($M) | Net Income ($M) | EPS ($) | Operating Cash Flow ($M) | Equity ($M) | Total Assets ($M) |
|---|---|---|---|---|---|---|---|
| 2016 | 9,766 | 1,281 | 702 | 7.14 | 1,288 | 4,533 | 10,318 |
| 2017 | 10,410 | 1,280 | 752 | 7.81 | 1,183 | 4,990 | 10,762 |
| 2018 | 10,772 | 1,175 | 780 | 8.32 | 1,341 | 5,389 | 11,265 |
| 2019 | 11,378 | 1,216 | 815 | 9.15 | 1,438 | 5,504 | 11,668 |
| 2020 | 11,559 | 1,358 | 944 | 11.03 | 2,360 | 6,317 | 13,477 |
| 2021 | 12,642 | 1,363 | 992 | 11.85 | 884 | 6,090 | 13,094 |
| 2022 | 13,399 | 1,004 | 676 | 9.15 | 996 | 5,921 | 13,494 |
| 2023 | 14,282 | 1,175 | 718 | 10.24 | 1,268 | 6,149 | 13,968 |
| 2024 | 15,828 | 1,682 | 1,142 | 16.82 | 2,067 | 6,666 | 14,470 |
| 2025 | 17,365 | 1,994 | 1,489 | 23.10 | 1,864 | 7,276 | 15,957 |
Fiscal years from the audited annual reports, oldest first. EBIT is the operating profit before interest and taxes; total assets are everything the company owns.
About the Company
Universal Health Services, Inc. besitzt und betreibt über ihre Tochtergesellschaften Akutkrankenhäuser sowie ambulante und verhaltensmedizinische Einrichtungen in den USA.
| Employees | 102,000 |
|---|---|
| Headquarters | King of Prussia, PA |
| Address | Universal Corporate Center, 19406-0958 King of Prussia, United States |
| Phone | 610 768 3300 |
| Website | uhs.com |
| IPO Date | 26. Mar 1990 |
| ISIN | US9139031002 |
| Stock Split | 2:1 on 12/16/2009 |
Management
| Name | Title | Birth Year |
|---|---|---|
| Alan B. Miller | Founder & Executive Chairman of the Board | 1938 |
| Marc D. Miller | CEO, President & Director | 1971 |
| Steve G. Filton | Executive VP, CFO & Secretary | 1958 |
| Edward H. Sim | Executive VP & President of Acute Care Division | 1972 |
| Darren P. Lehrich | Vice President of Investor Relations | 1972 |
| Matthew David Klein | Senior VP & General Counsel | – |
| Maria Zangardi | Senior VP of Human Resources & Corporate Officer | – |
| Michael S. Nelson | Senior Vice President of Strategic Services | – |
| Jim Clark | Senior Vice President of Finance - Acute Care Division | – |
| Thomas Day | Senior Vice President of Finance - Behavioral Health Division | – |
Executives per the latest required filings; titles kept in their original language. Source: fundamental data.
Chart
Interactive price chart (TradingView).
Data as of: August 3, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.